SI-BONE マネジメント
マネジメント 基準チェック /24
SI-BONEの CEO はLaura Francisで、 Apr2021年に任命され、 の在任期間は 5.08年です。 の年間総報酬は$ 7.45Mで、 9.2%給与と90.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.09%を直接所有しており、その価値は$ 7.13M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と15.4年です。
主要情報
Laura Francis
最高経営責任者
US$7.5m
報酬総額
| CEO給与比率 | 9.19% |
| CEO在任期間 | 5.1yrs |
| CEOの所有権 | 1.1% |
| 経営陣の平均在職期間 | 5.1yrs |
| 取締役会の平均在任期間 | 15.4yrs |
経営陣の近況
Recent updates
分析記事 • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...
ナラティブの更新 • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).ナラティブの更新 • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.ナラティブの更新 • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).ナラティブの更新 • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).ナラティブの更新 • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.ナラティブの更新 • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.ナラティブの更新 • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.分析記事 • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...分析記事 • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...分析記事 • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
新しいナラティブ • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.分析記事 • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...分析記事 • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...分析記事 • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...分析記事 • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...分析記事 • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jan 01
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$17m |
| Dec 31 2025 | US$7m | US$685k | -US$19m |
| Sep 30 2025 | n/a | n/a | -US$22m |
| Jun 30 2025 | n/a | n/a | -US$24m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$7m | US$652k | -US$31m |
| Sep 30 2024 | n/a | n/a | -US$37m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$43m |
| Dec 31 2023 | US$4m | US$622k | -US$43m |
| Sep 30 2023 | n/a | n/a | -US$44m |
| Jun 30 2023 | n/a | n/a | -US$48m |
| Mar 31 2023 | n/a | n/a | -US$55m |
| Dec 31 2022 | US$5m | US$604k | -US$61m |
| Sep 30 2022 | n/a | n/a | -US$65m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$3m | US$527k | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$43m |
| Dec 31 2020 | US$2m | US$386k | -US$44m |
| Sep 30 2020 | n/a | n/a | -US$44m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$2m | US$375k | -US$38m |
報酬と市場: Lauraの 総報酬 ($USD 7.45M ) は、 US市場 ($USD 3.71M ) の同規模の企業の平均を上回っています。
報酬と収益: Lauraの報酬は増加しましたが、会社は利益を上げていません。
CEO
Laura Francis (58 yo)
5.1yrs
在職期間
US$7,453,235
報酬
Ms. Laura A. Francis, MBA, has been an Independent Director of Bruker Corporation since February 18, 2025. She serves as Director at Galvanize Therapeutics, Inc. from November 2025. She serves as Chief Exe...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 18.1yrs | US$255.35k | 0.18% $ 1.2m | |
| CEO & Director | 5.1yrs | US$7.45m | 1.09% $ 7.1m | |
| COO & CFO | 5.1yrs | US$2.79m | 0.16% $ 1.0m | |
| Chief Business & Legal Affairs Officer | 9.8yrs | US$2.36m | 0.30% $ 2.0m | |
| Advisor | 9.8yrs | US$2.45m | 0.36% $ 2.4m | |
| Senior VP of Engineering & CTO | no data | データなし | データなし | |
| Vice President of Financial Planning & Analysis and Investor Relations | no data | データなし | データなし | |
| Vice President of Product & Marketing | less than a year | データなし | データなし | |
| Senior Vice President of Clinical | 4.9yrs | データなし | データなし | |
| Chief Medical Officer & VP of Medical Affairs | no data | データなし | データなし | |
| Chief Commercial Officer | 5.1yrs | データなし | データなし | |
| Senior Vice President of Market Access & Reimbursement | less than a year | データなし | データなし |
5.1yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: SIBNの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman | 18.1yrs | US$255.35k | 0.18% $ 1.2m | |
| CEO & Director | 5.1yrs | US$7.45m | 1.09% $ 7.1m | |
| Lead Independent Director | 18.1yrs | US$240.35k | 0.12% $ 774.0k | |
| Independent Director | 15.3yrs | US$217.60k | 0.39% $ 2.5m | |
| Independent Director | 6.4yrs | US$235.35k | 0.054% $ 357.5k | |
| Independent Director | 13.3yrs | US$215.35k | 0.28% $ 1.9m | |
| Member of Medical Advisory Board | 16.3yrs | データなし | データなし | |
| Member of Medical Advisory Board | 16.3yrs | データなし | データなし | |
| Member of Medical Advisory Board | 16.3yrs | データなし | データなし | |
| Member of Medical Advisory Board | 15.4yrs | データなし | データなし | |
| Independent Director | 5.2yrs | US$220.35k | 0.054% $ 356.1k | |
| Member of Surgeon Advisory Board | no data | データなし | データなし |
15.4yrs
平均在職期間
68yo
平均年齢
経験豊富なボード: SIBNの 取締役会 は経験豊富で 経験豊富 です ( 15.4年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/22 10:31 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
SI-BONE, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16
| アナリスト | 機関 |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |